{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:51:21Z","timestamp":1791269481174,"version":"4.1.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11536-z","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T11:24:38Z","timestamp":1775301878000},"page":"6769-6797","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting PI3K\u03b4 for lymphoma and immune diseases treatment: a review"],"prefix":"10.1007","volume":"30","author":[{"given":"Wenqing","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"issue":"1","key":"11536_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41392-022-00945-9","volume":"7","author":"Q Shen","year":"2022","unstructured":"Shen Q, Han Y, Wu K et al (2022) MrgprF acts as a tumor suppressor in cutaneous melanoma by restraining PI3K\/Akt signaling. Signal Transduct Target Ther 7(1):147. https:\/\/doi.org\/10.1038\/s41392-022-00945-9","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"11536_CR2","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG et al (2021) Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther 6(1):425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5","journal-title":"Signal Transduct Target Ther"},{"key":"11536_CR3","doi-asserted-by":"publisher","unstructured":"Nguyen T, Lau A, Bier J et al (2023) Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3K\u03b4 syndrome 2. J Exp Med 220(6). https:\/\/doi.org\/10.1084\/jem.20221020","DOI":"10.1084\/jem.20221020"},{"key":"11536_CR4","doi-asserted-by":"publisher","first-page":"100657","DOI":"10.1016\/j.jbior.2019.100657","volume":"75","author":"MK Rathinaswamy","year":"2020","unstructured":"Rathinaswamy MK, Burke JE (2020) Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease. Adv Biol Regul 75:100657. https:\/\/doi.org\/10.1016\/j.jbior.2019.100657","journal-title":"Adv Biol Regul"},{"issue":"1","key":"11536_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12865-025-00723-6","volume":"26","author":"K Vlachopoulou","year":"2025","unstructured":"Vlachopoulou K, Tutein Nolthenius J, Luscombe J et al (2025) Systematic literature reviews to identify epidemiological, clinical, economic and health-related quality of life evidence in activated PI3K\u03b4 syndrome (APDS). BMC Immunol 26(1):52. https:\/\/doi.org\/10.1186\/s12865-025-00723-6","journal-title":"BMC Immunol"},{"issue":"1","key":"11536_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-023-06895-2","volume":"199","author":"A Fiascarelli","year":"2023","unstructured":"Fiascarelli A, Merlino G, Capano S et al (2023) Antitumor activity of the PI3K \u03b4-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2\u2009+\u2009breast cancer. Breast Cancer Res Treat 199(1):13\u201323. https:\/\/doi.org\/10.1007\/s10549-023-06895-2","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"11536_CR7","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1073\/pnas.94.9.4330","volume":"94","author":"B Vanhaesebroeck","year":"1997","unstructured":"Vanhaesebroeck B, Welham MJ, Kotani K et al (1997) P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A 94(9):4330\u20134335. https:\/\/doi.org\/10.1073\/pnas.94.9.4330","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"11536_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/dnares\/4.5.355","volume":"4","author":"N Seki","year":"1997","unstructured":"Seki N, Nimura Y, Ohira M et al (1997) Identification and chromosome assignment of a human gene encoding a novel phosphatidylinositol-3 kinase. DNA Res 4(5):355\u2013358. https:\/\/doi.org\/10.1093\/dnares\/4.5.355","journal-title":"DNA Res"},{"issue":"31","key":"11536_CR9","doi-asserted-by":"publisher","first-page":"19236","DOI":"10.1074\/jbc.272.31.19236","volume":"272","author":"D Chantry","year":"1997","unstructured":"Chantry D, Vojtek A, Kashishian A et al (1997) p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 272(31):19236\u201319241. https:\/\/doi.org\/10.1074\/jbc.272.31.19236","journal-title":"J Biol Chem"},{"issue":"1","key":"11536_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21873\/cdp.10279","volume":"4","author":"DACM AK","year":"2024","unstructured":"AK DACM, Machado CB, FMC DEPP et al (2024) Development and clinical applications of PI3K\/AKT\/mTOR pathway inhibitors as a therapeutic option for leukemias. Cancer Diagn Progn 4(1):9\u201324. https:\/\/doi.org\/10.21873\/cdp.10279","journal-title":"Cancer Diagn Progn"},{"key":"11536_CR11","doi-asserted-by":"publisher","unstructured":"Tsay A, Wang JC (2023) The role of PIK3R1 in metabolic function and insulin sensitivity. Int J Mol Sci 24(16). https:\/\/doi.org\/10.3390\/ijms241612665","DOI":"10.3390\/ijms241612665"},{"issue":"5","key":"11536_CR12","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1006\/bbrc.2001.4281","volume":"280","author":"E Clayton","year":"2001","unstructured":"Clayton E, McAdam S, Coadwell J et al (2001) Structural organization of the mouse phosphatidylinositol 3-kinase p110d gene. Biochem Biophys Res Commun 280(5):1328\u20131332. https:\/\/doi.org\/10.1006\/bbrc.2001.4281","journal-title":"Biochem Biophys Res Commun"},{"issue":"7505","key":"11536_CR13","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nature13444","volume":"510","author":"K Ali","year":"2014","unstructured":"Ali K, Soond DR, Pineiro R et al (2014) Inactivation of PI(3)K p110\u03b4 breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510(7505):407\u2013411. https:\/\/doi.org\/10.1038\/nature13444","journal-title":"Nature"},{"issue":"1","key":"11536_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-024-02072-1","volume":"23","author":"H Li","year":"2024","unstructured":"Li H, Wen X, Ren Y et al (2024) Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions. Mol Cancer 23(1):164. https:\/\/doi.org\/10.1186\/s12943-024-02072-1","journal-title":"Mol Cancer"},{"key":"11536_CR15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1017\/s1462399411002109","volume":"14","author":"SM Schultze","year":"2012","unstructured":"Schultze SM, Hemmings BA, Niessen M et al (2012) PI3K\/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Expert Rev Mol Med 14:e1. https:\/\/doi.org\/10.1017\/s1462399411002109","journal-title":"Expert Rev Mol Med"},{"key":"11536_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.37349\/ent.2021.00008","volume":"1","author":"K Tariq","year":"2021","unstructured":"Tariq K, Luikart BW (2021) Striking a balance: PIP(2) and PIP(3) signaling in neuronal health and disease. Explor Neuroprotective Ther 1:86\u2013100. https:\/\/doi.org\/10.37349\/ent.2021.00008","journal-title":"Explor Neuroprotective Ther"},{"issue":"2","key":"11536_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.oooo.2021.08.018","volume":"133","author":"IP Gomes","year":"2022","unstructured":"Gomes IP, Guimar\u00e3es LM, Pereira TDSF et al (2022) Assessment of PI3K\/AKT and MAPK\/ERK pathways activation in oral lymphatic malformations. Oral Surg Oral Med Oral Pathol Oral Radiol 133(2):216\u2013220. https:\/\/doi.org\/10.1016\/j.oooo.2021.08.018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"2","key":"11536_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrd4204","volume":"13","author":"DA Fruman","year":"2014","unstructured":"Fruman DA, Rommel C (2014) PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13(2):140\u2013156. https:\/\/doi.org\/10.1038\/nrd4204","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"11536_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY et al (2023) PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 22(1):138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6","journal-title":"Mol Cancer"},{"key":"11536_CR20","doi-asserted-by":"publisher","first-page":"819128","DOI":"10.3389\/fonc.2022.819128","volume":"12","author":"Y Peng","year":"2022","unstructured":"Peng Y, Wang Y, Zhou C et al (2022) PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: Are we making headway? Front Oncol 12:819128. https:\/\/doi.org\/10.3389\/fonc.2022.819128","journal-title":"Front Oncol"},{"issue":"6","key":"11536_CR21","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.bbalip.2014.12.006","volume":"1851","author":"PT Hawkins","year":"2015","unstructured":"Hawkins PT, Stephens LR (2015) PI3K signalling in inflammation. Biochim Biophys Acta 1851(6):882\u2013897. https:\/\/doi.org\/10.1016\/j.bbalip.2014.12.006","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"11536_CR22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","volume":"14","author":"H Wang","year":"2021","unstructured":"Wang H, Guo M, Wei H et al (2021) Targeting MCL-1 in cancer: current status and perspectives. J Hematol Oncol 14(1):67. https:\/\/doi.org\/10.1186\/s13045-021-01079-1","journal-title":"J Hematol Oncol"},{"issue":"16","key":"11536_CR23","doi-asserted-by":"publisher","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","volume":"118","author":"FK Stevenson","year":"2011","unstructured":"Stevenson FK, Krysov S, Davies AJ et al (2011) B-cell receptor signaling in chronic lymphocytic leukemia. Blood 118(16):4313\u20134320. https:\/\/doi.org\/10.1182\/blood-2011-06-338855","journal-title":"Blood"},{"issue":"1","key":"11536_CR24","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","volume":"117","author":"P P\u00e9rez-Gal\u00e1n","year":"2011","unstructured":"P\u00e9rez-Gal\u00e1n P, Dreyling M, Wiestner A (2011) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117(1):26\u201338. https:\/\/doi.org\/10.1182\/blood-2010-04-189977","journal-title":"Blood"},{"issue":"10","key":"11536_CR25","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1182\/blood.2022019419","volume":"142","author":"SL Sloan","year":"2023","unstructured":"Sloan SL, Brown F, Long M et al (2023) PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma. Blood 142(10):887\u2013902. https:\/\/doi.org\/10.1182\/blood.2022019419","journal-title":"Blood"},{"issue":"5","key":"11536_CR26","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.hoc.2020.05.002","volume":"34","author":"A Navarro","year":"2020","unstructured":"Navarro A, Be\u00e0 S, Jares P et al (2020) Molecular pathogenesis of mantle Cell lymphoma. Hematol Oncol Clin North Am 34(5):795\u2013807. https:\/\/doi.org\/10.1016\/j.hoc.2020.05.002","journal-title":"Hematol Oncol Clin North Am"},{"issue":"12","key":"11536_CR27","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","volume":"34","author":"JA Burger","year":"2013","unstructured":"Burger JA, Chiorazzi N (2013) B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 34(12):592\u2013601. https:\/\/doi.org\/10.1016\/j.it.2013.07.002","journal-title":"Trends Immunol"},{"issue":"3","key":"11536_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.bbamcr.2015.07.009","volume":"1863","author":"E Ten Hacken","year":"2016","unstructured":"Ten Hacken E, Burger JA (2016) Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochim Biophys Acta 1863(3):401\u2013413. https:\/\/doi.org\/10.1016\/j.bbamcr.2015.07.009","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"11536_CR29","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1080\/13543784.2017.1384815","volume":"26","author":"BL Lampson","year":"2017","unstructured":"Lampson BL, Brown JR (2017) PI3K\u03b4-selective and PI3K\u03b1\/\u03b4-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs 26(11):1267\u20131279. https:\/\/doi.org\/10.1080\/13543784.2017.1384815","journal-title":"Expert Opin Investig Drugs"},{"key":"11536_CR30","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.2147\/dddt.S142406","volume":"12","author":"G Krause","year":"2018","unstructured":"Krause G, Hassenr\u00fcck F, Hallek M (2018) Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib. Drug Des Devel Ther 12:2577\u20132590. https:\/\/doi.org\/10.2147\/dddt.S142406","journal-title":"Drug Des Devel Ther"},{"key":"11536_CR31","doi-asserted-by":"publisher","unstructured":"Nepstad I, Hatfield KJ, Gr\u00f8nnings\u00e6ter IS et al (2020) The PI3K-Akt-mTOR signaling pathway in human acute myeloid;eukemia (AML) cells. Int J Mol Sci 21(8). https:\/\/doi.org\/10.3390\/ijms21082907","DOI":"10.3390\/ijms21082907"},{"key":"11536_CR32","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/978-3-031-06566-8_17","volume":"436","author":"HN Kim","year":"2022","unstructured":"Kim HN, Ogana H, Sanchez V et al (2022) PI3K targeting in non-solid cancer. Curr Top Microbiol Immunol 436:393\u2013407. https:\/\/doi.org\/10.1007\/978-3-031-06566-8_17","journal-title":"Curr Top Microbiol Immunol"},{"key":"11536_CR33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fimmu.2012.00256","volume":"3","author":"KD Puri","year":"2012","unstructured":"Puri KD, Gold MR (2012) Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol 3:256. https:\/\/doi.org\/10.3389\/fimmu.2012.00256","journal-title":"Front Immunol"},{"issue":"7","key":"11536_CR34","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41419-024-06848-7","volume":"15","author":"YN Zheng","year":"2024","unstructured":"Zheng YN, Lou SY, Lu J et al (2024) Selective PI3K\u03b4 inhibitor TYM-3-98 suppresses AKT\/mTOR\/SREBP1-mediated lipogenesis and promotes ferroptosis in KRAS-mutant colorectal cancer. Cell Death Dis 15(7):474. https:\/\/doi.org\/10.1038\/s41419-024-06848-7","journal-title":"Cell Death Dis"},{"issue":"8","key":"11536_CR35","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1038\/s41590-024-01890-1","volume":"25","author":"SM Lanahan","year":"2024","unstructured":"Lanahan SM, Yang L, Jones KM et al (2024) PI3K\u03b3 in B cells promotes antibody responses and generation of antibody-secreting cells. Nat Immunol 25(8):1422\u20131431. https:\/\/doi.org\/10.1038\/s41590-024-01890-1","journal-title":"Nat Immunol"},{"key":"11536_CR36","doi-asserted-by":"publisher","first-page":"708908","DOI":"10.3389\/fimmu.2021.708908","volume":"12","author":"KH Johansen","year":"2021","unstructured":"Johansen KH, Golec DP, Thomsen JH et al (2021) PI3K in T Cell adhesion and trafficking. Front Immunol 12:708908. https:\/\/doi.org\/10.3389\/fimmu.2021.708908","journal-title":"Front Immunol"},{"key":"11536_CR37","doi-asserted-by":"publisher","unstructured":"Tarantelli C, Argnani L, Zinzani PL et al (2021) PI3K\u03b4 inhibitors as immunomodulatory agents for the treatment of lymphoma patients. Cancers (Basel) 13(21). https:\/\/doi.org\/10.3390\/cancers13215535","DOI":"10.3390\/cancers13215535"},{"key":"11536_CR38","doi-asserted-by":"publisher","unstructured":"Tan CL, Kuchroo JR, Sage PT et al (2021) PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. J Exp Med 218(1). https:\/\/doi.org\/10.1084\/jem.20182232","DOI":"10.1084\/jem.20182232"},{"issue":"11","key":"11536_CR39","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1182\/blood-2007-08-105395","volume":"111","author":"S Mittal","year":"2008","unstructured":"Mittal S, Marshall NA, Duncan L et al (2008) Local and systemic induction of CD4\u2009+\u2009CD25+ regulatory T-cell population by non-Hodgkin lymphoma. Blood 111(11):5359\u20135370. https:\/\/doi.org\/10.1182\/blood-2007-08-105395","journal-title":"Blood"},{"issue":"6","key":"11536_CR40","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/s41375-018-0318-3","volume":"33","author":"BS Hanna","year":"2019","unstructured":"Hanna BS, Roessner PM, Scheffold A et al (2019) PI3K\u03b4 inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia. Leukemia 33(6):1427\u20131438. https:\/\/doi.org\/10.1038\/s41375-018-0318-3","journal-title":"Leukemia"},{"issue":"8","key":"11536_CR41","doi-asserted-by":"publisher","first-page":"e18498","DOI":"10.1016\/j.heliyon.2023.e18498","volume":"9","author":"Y Li","year":"2023","unstructured":"Li Y, Li Y, Yang Y et al (2023) Synergistic efficacy of PI3K\u03b4 inhibitor with anti-PD-1 mAbs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer. Heliyon 9(8):e18498. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18498","journal-title":"Heliyon"},{"issue":"4","key":"11536_CR42","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1158\/2767-9764.CRC-22-0477","volume":"3","author":"Z Johnson","year":"2023","unstructured":"Johnson Z, Tarantelli C, Civanelli E et al (2023) IOA-244 is a non-ATP-competitive, highly selective, tolerable PI3K delta inhibitor that targets solid tumors and breaks immune tolerance. Cancer Res Commun 3(4):576\u2013591. https:\/\/doi.org\/10.1158\/2767-9764.CRC-22-0477","journal-title":"Cancer Res Commun"},{"issue":"3","key":"11536_CR43","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s12016-019-08738-9","volume":"59","author":"M Jamee","year":"2020","unstructured":"Jamee M, Moniri S, Zaki-Dizaji M et al (2020) Clinical, immunological, and genetic features in patients with activated PI3K\u03b4 syndrome (APDS): a systematic review. Clin Rev Allergy Immunol 59(3):323\u2013333. https:\/\/doi.org\/10.1007\/s12016-019-08738-9","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"11536_CR44","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/cyto.b.21956","volume":"100","author":"L Del Pino-Molina","year":"2021","unstructured":"Del Pino-Molina L, Torres Canizales JM, Rodr\u00edguez-Pena R et al (2021) Evaluation of B-cell intracellular signaling by monitoring the PI3K-Akt axis in patients with common variable immunodeficiency and activated phosphoinositide 3-kinase delta syndrome. Cytometry B Clin Cytom 100(4):460\u2013466. https:\/\/doi.org\/10.1002\/cyto.b.21956","journal-title":"Cytometry B Clin Cytom"},{"issue":"9","key":"11536_CR45","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2022018546","volume":"141","author":"VK Rao","year":"2023","unstructured":"Rao VK, Webster S, \u0160ediv\u00e1 A et al (2023) A randomized, placebo-controlled phase 3 trial of the PI3K\u03b4 inhibitor leniolisib for activated PI3K\u03b4 syndrome. Blood 141(9):971\u2013983. https:\/\/doi.org\/10.1182\/blood.2022018546","journal-title":"Blood"},{"issue":"9","key":"11536_CR46","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1021\/acsmedchemlett.7b00293","volume":"8","author":"K Hoegenauer","year":"2017","unstructured":"Hoegenauer K, Soldermann N, Z\u00e9cri F et al (2017) Discovery of CDZ173 (Leniolisib), representing a structurally novel class of PI3K delta-selective inhibitors. ACS Med Chem Lett 8(9):975\u2013980. https:\/\/doi.org\/10.1021\/acsmedchemlett.7b00293","journal-title":"ACS Med Chem Lett"},{"issue":"11","key":"11536_CR47","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/art.43254","volume":"77","author":"JP Lim","year":"2025","unstructured":"Lim JP, Ahmadian M, Du H et al (2025) Precision medicine in pediatric autoimmunity: leniolisib treatment of childhood-onset lupus nephritis due to activated phosphoinositide 3-kinase \u03b4 syndrome. Arthritis Rheumatol 77(11):1596\u20131160. https:\/\/doi.org\/10.1002\/art.43254","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"11536_CR48","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.jaci.2015.12.1313","volume":"137","author":"F Horak","year":"2016","unstructured":"Horak F, Puri KD, Steiner BH et al (2016) Randomized phase 1 study of the phosphatidylinositol 3-kinase \u03b4 inhibitor idelalisib in patients with allergic rhinitis. J Allergy Clin Immunol 137(6):1733\u20131741. https:\/\/doi.org\/10.1016\/j.jaci.2015.12.1313","journal-title":"J Allergy Clin Immunol"},{"issue":"59","key":"11536_CR49","doi-asserted-by":"publisher","first-page":"PA2122","DOI":"10.1183\/13993003","volume":"46","author":"T Schmalbach","year":"2025","unstructured":"Schmalbach T, Fuhr R, Albayaty M et al (2025) Duvelisib, a PI3K-\u03b4,\u03b3 inhibitor, in subjects with mild asthma. Eur Respir J 46(59):PA2122. https:\/\/doi.org\/10.1183\/13993003","journal-title":"Eur Respir J"},{"issue":"14","key":"11536_CR50","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s40265-014-0285-6","volume":"74","author":"A Markham","year":"2014","unstructured":"Markham A (2014) Idelalisib: first global approval. Drugs 74(14):1701\u20131707. https:\/\/doi.org\/10.1007\/s40265-014-0285-6","journal-title":"Drugs"},{"issue":"3","key":"11536_CR51","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1182\/blood-2016-02-702761","volume":"128","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Fowler NH (2016) Idelalisib in the management of lymphoma. Blood 128(3):331\u2013336. https:\/\/doi.org\/10.1182\/blood-2016-02-702761","journal-title":"Blood"},{"issue":"24","key":"11536_CR52","doi-asserted-by":"publisher","first-page":"11185","DOI":"10.1111\/jcmm.17039","volume":"25","author":"X Li","year":"2021","unstructured":"Li X, Li H, Zhang S et al (2021) Protective effect of Idelalisib on carbon tetrachloride-induced liver fibrosis via microRNA-124-3P\/phosphatidylinositol-3-hydroxykinase signalling pathway. J Cell Mol Med 25(24):11185\u201311197. https:\/\/doi.org\/10.1111\/jcmm.17039","journal-title":"J Cell Mol Med"},{"key":"11536_CR53","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12935-020-01431-4","volume":"20","author":"LM Sklarz","year":"2020","unstructured":"Sklarz LM, Gladbach YS, Ernst M et al (2020) Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that induce anti-proliferative effects in B lymphoblastic leukaemia cell lines. Cancer Cell Int 20:390. https:\/\/doi.org\/10.1186\/s12935-020-01431-4","journal-title":"Cancer Cell Int"},{"issue":"22","key":"11536_CR54","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","volume":"123","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, Spurgeon SE, Furman RR et al (2014) A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL). Blood 123(22):3398\u20133405. https:\/\/doi.org\/10.1182\/blood-2013-11-537555","journal-title":"Blood"},{"issue":"22","key":"11536_CR55","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, Kahl BS, Leonard JP et al (2014) Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-\u03b4, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 123(22):3406\u20133413. https:\/\/doi.org\/10.1182\/blood-2013-11-538546","journal-title":"Blood"},{"issue":"3","key":"11536_CR56","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1097\/hs9.0000000000000039","volume":"2","author":"SE Coutre","year":"2018","unstructured":"Coutre SE, Flinn IW, de Vos S et al (2018) Idelalisib in combination with rituximab or bendamustine or both in patients with relapsed\/refractory chronic lymphocytic leukemia. Hemasphere 2(3):e39. https:\/\/doi.org\/10.1097\/hs9.0000000000000039","journal-title":"Hemasphere"},{"issue":"11","key":"11536_CR57","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","volume":"370","author":"AK Gopal","year":"2014","unstructured":"Gopal AK, Kahl BS, de Vos S et al (2014) PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370(11):1008\u20131018. https:\/\/doi.org\/10.1056\/NEJMoa1314583","journal-title":"N Engl J Med"},{"issue":"11","key":"11536_CR58","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE et al (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370(11):997\u20131007. https:\/\/doi.org\/10.1056\/NEJMoa1315226","journal-title":"N Engl J Med"},{"issue":"2","key":"11536_CR59","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","volume":"128","author":"BL Lampson","year":"2016","unstructured":"Lampson BL, Kasar SN, Matos TR et al (2016) Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 128(2):195\u2013203. https:\/\/doi.org\/10.1182\/blood-2016-03-707133","journal-title":"Blood"},{"issue":"9","key":"11536_CR60","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/bloodadvances.2020003895","volume":"5","author":"C Tomowiak","year":"2021","unstructured":"Tomowiak C, Poulain S, Herbaux C et al (2021) Obinutuzumab and idelalisib in symptomatic patients with relapsed\/refractory Waldenstr\u00f6m macroglobulinemia. Blood Adv 5(9):2438\u20132446. https:\/\/doi.org\/10.1182\/bloodadvances.2020003895","journal-title":"Blood Adv"},{"issue":"5","key":"11536_CR61","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/annonc\/mdx028","volume":"28","author":"AK Gopal","year":"2017","unstructured":"Gopal AK, Fanale MA, Moskowitz CH et al (2017) Phase II study of idelalisib, a selective inhibitor of PI3K\u03b4, for relapsed\/refractory classical Hodgkin lymphoma. Ann Oncol 28(5):1057\u20131063. https:\/\/doi.org\/10.1093\/annonc\/mdx028","journal-title":"Ann Oncol"},{"issue":"16","key":"11536_CR62","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/jco.18.01460","volume":"37","author":"JP Sharman","year":"2019","unstructured":"Sharman JP, Coutre SE, Furman RR et al (2019) Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed Chronic lymphocytic leukemia. J Clin Oncol 37(16):1391\u20131402. https:\/\/doi.org\/10.1200\/jco.18.01460","journal-title":"J Clin Oncol"},{"issue":"19","key":"11536_CR63","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1182\/blood.2019001795","volume":"134","author":"K Patel","year":"2019","unstructured":"Patel K, Danilov AV, Pagel JM (2019) Duvelisib for CLL\/SLL and follicular non-Hodgkin lymphoma. Blood 134(19):1573\u20131577. https:\/\/doi.org\/10.1182\/blood.2019001795","journal-title":"Blood"},{"issue":"8","key":"11536_CR64","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","volume":"131","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, O\u2019Brien S, Kahl B et al (2018) Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies. Blood 131(8):877\u2013887. https:\/\/doi.org\/10.1182\/blood-2017-05-786566","journal-title":"Blood"},{"issue":"11","key":"11536_CR65","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1200\/jco.18.00915","volume":"37","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Miller CB, Ardeshna KM et al (2019) DYNAMO: A phase II study of duvelisib (IPI-145) in patients with refractory indolent non-hodgkin lymphoma. J Clin Oncol 37(11):912\u2013922. https:\/\/doi.org\/10.1200\/jco.18.00915","journal-title":"J Clin Oncol"},{"issue":"23","key":"11536_CR66","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","volume":"132","author":"IW Flinn","year":"2018","unstructured":"Flinn IW, Hillmen P, Montillo M et al (2018) The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL. Blood 132(23):2446\u20132455. https:\/\/doi.org\/10.1182\/blood-2018-05-850461","journal-title":"Blood"},{"issue":"9","key":"11536_CR67","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41591-024-03076-6","volume":"30","author":"SM Horwitz","year":"2024","unstructured":"Horwitz SM, Nirmal AJ, Rahman J et al (2024) Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial. Nat Med 30(9):2517\u20132527. https:\/\/doi.org\/10.1038\/s41591-024-03076-6","journal-title":"Nat Med"},{"issue":"11","key":"11536_CR68","doi-asserted-by":"publisher","first-page":"ofad518","DOI":"10.1093\/ofid\/ofad518","volume":"10","author":"SR Goldsmith","year":"2023","unstructured":"Goldsmith SR, Covut F, Fiala M et al (2023) Duvelisib for critically Ill patients with coronavirus disease 2019: An investigator-initiated, randomized, placebo-controlled, double-blind pilot trial. Open Forum Infect Dis 10(11):ofad518. https:\/\/doi.org\/10.1093\/ofid\/ofad518","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"11536_CR69","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/ajh.25634","volume":"94","author":"IW Flinn","year":"2019","unstructured":"Flinn IW, Cherry MA, Maris MB et al (2019) Combination trial of duvelisib (IPI-145) with rituximab or bendamustine\/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia. Am J Hematol 94(12):1325\u20131334. https:\/\/doi.org\/10.1002\/ajh.25634","journal-title":"Am J Hematol"},{"issue":"4","key":"11536_CR70","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41375-020-01010-6","volume":"35","author":"MS Davids","year":"2021","unstructured":"Davids MS, Fisher DC, Tyekucheva S et al (2021) A phase 1b\/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients. Leukemia 35(4):1064\u20131072. https:\/\/doi.org\/10.1038\/s41375-020-01010-6","journal-title":"Leukemia"},{"issue":"7","key":"11536_CR71","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s40265-021-01504-2","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S, Keam SJ, Umbralisib (2021) First approval. Drugs 81(7):857\u2013866. https:\/\/doi.org\/10.1007\/s40265-021-01504-2","journal-title":"Drugs"},{"issue":"1","key":"11536_CR72","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-021-01140-z","volume":"14","author":"B Jiang","year":"2021","unstructured":"Jiang B, Qi J, Song Y et al (2021) Phase 1 clinical trial of the PI3K\u03b4 inhibitor YY-20394 in patients with B-cell hematological malignancies. J Hematol Oncol 14(1):130. https:\/\/doi.org\/10.1186\/s13045-021-01140-z","journal-title":"J Hematol Oncol"},{"issue":"1","key":"11536_CR73","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12935-025-03669-2","volume":"25","author":"P Sun","year":"2025","unstructured":"Sun P, Cen H, Yang H et al (2025) PI3K\u03b4 inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib\/II trial. Cancer Cell Int 25(1):39. https:\/\/doi.org\/10.1186\/s12935-025-03669-2","journal-title":"Cancer Cell Int"},{"issue":"8","key":"11536_CR74","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/1078-0432.Ccr-22-2939","volume":"29","author":"T Wang","year":"2023","unstructured":"Wang T, Sun X, Qiu L et al (2023) The oral PI3K\u03b4 inhibitor linperlisib for the treatment of relapsed and\/or refractory follicular lymphoma: A phase II, single-arm, open-label clinical trial. Clin Cancer Res 29(8):1440\u20131449. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-2939","journal-title":"Clin Cancer Res"},{"issue":"2","key":"11536_CR75","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10147-024-02657-2","volume":"30","author":"J Li","year":"2025","unstructured":"Li J, Xue J, Liu T et al (2025) Phase Ib study of the oral PI3K\u03b4 inhibitor linperlisib in patients with advanced solid tumors. Int J Clin Oncol 30(2):241\u2013251. https:\/\/doi.org\/10.1007\/s10147-024-02657-2","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"11536_CR76","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40265-023-01895-4","volume":"83","author":"S Duggan","year":"2023","unstructured":"Duggan S, Al-Salama ZT, Leniolisib (2023) First approval. Drugs 83(10):943\u2013948. https:\/\/doi.org\/10.1007\/s40265-023-01895-4","journal-title":"Drugs"},{"issue":"16","key":"11536_CR77","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","volume":"133","author":"A Forero-Torres","year":"2019","unstructured":"Forero-Torres A, Ramchandren R, Yacoub A et al (2019) Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood 133(16):1742\u20131752. https:\/\/doi.org\/10.1182\/blood-2018-08-867499","journal-title":"Blood"},{"issue":"8","key":"11536_CR78","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1002\/hem3.138","volume":"8","author":"AD Zelenetz","year":"2024","unstructured":"Zelenetz AD, Jurczak W, Ribrag V et al (2024) The PI3K\u03b4 inhibitor zandelisib on intermittent dosing in relapsed\/refractory follicular lymphoma: Results from a global phase 2 study. Hemasphere 8(8):e138. https:\/\/doi.org\/10.1002\/hem3.138","journal-title":"Hemasphere"},{"issue":"7","key":"11536_CR79","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1080\/10428194.2022.2043301","volume":"63","author":"PM Barr","year":"2022","unstructured":"Barr PM, Smith SD, Roschewski MJ et al (2022) Phase 1\/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed\/refractory B-cell non-hodgkin lymphoma. Leuk Lymphoma 63(7):1728\u20131732. https:\/\/doi.org\/10.1080\/10428194.2022.2043301","journal-title":"Leuk Lymphoma"},{"issue":"11","key":"11536_CR80","doi-asserted-by":"publisher","first-page":"11437","DOI":"10.1021\/acs.jmedchem.5c00408","volume":"68","author":"B Yuan","year":"2025","unstructured":"Yuan B, Liu J, Wu Y et al (2025) Lysine-targeted covalent strategy leading to the discovery of novel potent PROTAC-based PI3K\u03b4 degraders. J Med Chem 68(11):11437\u201311467. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00408","journal-title":"J Med Chem"},{"issue":"7911","key":"11536_CR81","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41586-022-04685-2","volume":"605","author":"S Eschweiler","year":"2022","unstructured":"Eschweiler S, Ram\u00edrez-Su\u00e1stegui C, Li Y et al (2022) Intermittent PI3K\u03b4 inhibition sustains anti-tumour immunity and curbs irAEs. Nature 605(7911):741\u2013746. https:\/\/doi.org\/10.1038\/s41586-022-04685-2","journal-title":"Nature"},{"issue":"25","key":"11536_CR82","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","volume":"126","author":"SM O\u2019Brien","year":"2015","unstructured":"O\u2019Brien SM, Lamanna N, Kipps TJ et al (2015) A phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia. Blood 126(25):2686\u20132694. https:\/\/doi.org\/10.1182\/blood-2015-03-630947","journal-title":"Blood"},{"issue":"11","key":"11536_CR83","doi-asserted-by":"publisher","first-page":"e969","DOI":"10.1016\/j.clml.2025.07.011","volume":"25","author":"V Liao","year":"2025","unstructured":"Liao V, Ganesan N, Dusza S et al (2025) Dermatologic adverse events in patients receiving duvelisib single-agent and combination therapies. Clin Lymphoma Myeloma Leuk 25(11):e969\u2013e975. https:\/\/doi.org\/10.1016\/j.clml.2025.07.011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"11536_CR84","doi-asserted-by":"publisher","first-page":"e234113","DOI":"10.1136\/bcr-2019-234113","volume":"13","author":"LM Ward","year":"2020","unstructured":"Ward LM, Peluso MJ, Budak JZ et al (2020) Opportunistic coinfection with pneumocystis jirovecii and coccidioides immitis associated with idelalisib treatment in a patient with chronic lymphocytic leukaemia. BMJ Case Rep 13(4):e234113. https:\/\/doi.org\/10.1136\/bcr-2019-234113","journal-title":"BMJ Case Rep"},{"issue":"2","key":"11536_CR85","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nchembio.293","volume":"6","author":"A Berndt","year":"2010","unstructured":"Berndt A, Miller S, Williams O et al (2010) The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol 6(2):117\u2013124. https:\/\/doi.org\/10.1038\/nchembio.293","journal-title":"Nat Chem Biol"},{"issue":"13","key":"11536_CR86","doi-asserted-by":"publisher","first-page":"8439","DOI":"10.1074\/jbc.M114.634683","volume":"290","author":"JR Somoza","year":"2015","unstructured":"Somoza JR, Koditek D, Villase\u00f1or AG et al (2015) Structural, biochemical, and biophysical characterization of idelalisib binding to phosphoinositide 3-kinase \u03b4. J Biol Chem 290(13):8439\u20138446. https:\/\/doi.org\/10.1074\/jbc.M114.634683","journal-title":"J Biol Chem"},{"issue":"19","key":"11536_CR87","doi-asserted-by":"publisher","first-page":"127457","DOI":"10.1016\/j.bmcl.2020.127457","volume":"30","author":"J Sun","year":"2020","unstructured":"Sun J, Feng Y, Huang Y et al (2020) Research advances on selective phosphatidylinositol 3 kinase \u03b4 (PI3K\u03b4) inhibitors. Bioorg Med Chem Lett 30(19):127457. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127457","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"11536_CR88","doi-asserted-by":"publisher","first-page":"2304625","DOI":"10.1080\/14756366.2024.2304625","volume":"39","author":"NM Ahmed","year":"2024","unstructured":"Ahmed NM, Mohamed MS, Awad SM et al (2024) Design, synthesis, molecular modelling and biological evaluation of novel 6-amino-5-cyano-2-thiopyrimidine derivatives as potent anticancer agents against leukemia and apoptotic inducers. J Enzyme Inhib Med Chem 39(1):2304625. https:\/\/doi.org\/10.1080\/14756366.2024.2304625","journal-title":"J Enzyme Inhib Med Chem"},{"key":"11536_CR89","doi-asserted-by":"publisher","unstructured":"Ali AM, Makki AA, Ibraheem W et al (2023) Design of novel phosphatidylinositol 3-Kinase inhibitors for non-hodgkin\u2019s lymphoma: Molecular docking, molecular dynamics, and density functional theory studies on gold nanoparticles. Molecules 28(5). https:\/\/doi.org\/10.3390\/molecules28052289","DOI":"10.3390\/molecules28052289"},{"issue":"5","key":"11536_CR90","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.62347\/jcgq1004","volume":"15","author":"K Kunieda","year":"2025","unstructured":"Kunieda K, Nagiri C, Watanabe M et al (2025) A long-lasting PI3K\u03b4 inhibitor zandelisib forms a water-shielded hydrogen bond with p110\u03b4 and demonstrates sustained inhibitory effects. Am J Cancer Res 15(5):2097\u20132110. https:\/\/doi.org\/10.62347\/jcgq1004","journal-title":"Am J Cancer Res"},{"issue":"11","key":"11536_CR91","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1021\/acsmedchemlett.9b00334","volume":"10","author":"EW Yue","year":"2019","unstructured":"Yue EW, Li YL, Douty B et al (2019) INCB050465 (Parsaclisib), a novel next-generation inhibitor of phosphoinositide 3-kinase delta (PI3K\u03b4). ACS Med Chem Lett 10(11):1554\u20131560. https:\/\/doi.org\/10.1021\/acsmedchemlett.9b00334","journal-title":"ACS Med Chem Lett"},{"issue":"10","key":"11536_CR92","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.1021\/acs.jmedchem.8b01492","volume":"62","author":"AE Garces","year":"2019","unstructured":"Garces AE, Stocks MJ (2019) Class 1 PI3K clinical candidates and recent inhibitor design strategies: A medicinal chemistry perspective. J Med Chem 62(10):4815\u20134850. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01492","journal-title":"J Med Chem"},{"key":"11536_CR93","doi-asserted-by":"publisher","unstructured":"Rodrigues DA, Sagrillo FS, Fraga CAM, Duvelisib (2019) A 2018 novel FDA-approved small molecule inhibiting phosphoinositide 3-Kinases. Pharmaceuticals (Basel) 12(2). https:\/\/doi.org\/10.3390\/ph12020069","DOI":"10.3390\/ph12020069"},{"key":"11536_CR94","doi-asserted-by":"publisher","unstructured":"Vishakha S, Navneesh N, Kurmi BD et al (2024) An expedition on synthetic methodology of FDA-approved anticancer drugs (2018-2021). Anticancer Agents Med Chem 24(8):590-626. https:\/\/doi.org\/10.2174\/0118715206259585240105051941","DOI":"10.2174\/0118715206259585240105051941"},{"key":"11536_CR95","unstructured":"Xu ZS, Lou YT (2017) Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof. US 9656996 B2, ; 5 (23). https:\/\/data.epo.org\/publication-server\/rest\/v1.0\/publication-dates\/20200527\/patents\/EP3059238NWB1\/document.html"},{"key":"11536_CR96","doi-asserted-by":"publisher","first-page":"1337436","DOI":"10.3389\/fphar.2024.1337436","volume":"15","author":"SK De","year":"2024","unstructured":"De SK (2024) Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome. Front Pharmacol 15:1337436. https:\/\/doi.org\/10.3389\/fphar.2024.1337436","journal-title":"Front Pharmacol"},{"issue":"10","key":"11536_CR97","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/jamaophthalmol.2019.2512","volume":"137","author":"S Johnson","year":"2019","unstructured":"Johnson S, Buessing M, O\u2019Connell T et al (2019) Cost-effectiveness of voretigene neparvovec-rzyl vs standard care for RPE65-Mediated inherited retinal disease. JAMA Ophthalmol 137(10):1115\u20131123. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.2512","journal-title":"JAMA Ophthalmol"},{"issue":"35","key":"11536_CR98","doi-asserted-by":"publisher","first-page":"10210","DOI":"10.1002\/anie.201601967","volume":"55","author":"Y Tu","year":"2016","unstructured":"Tu Y (2016) Artemisinin-A fift from traditional chinese medicine to the world (Nobel Lecture). Angew Chem Int Ed Engl 55(35):10210\u201310226. https:\/\/doi.org\/10.1002\/anie.201601967","journal-title":"Angew Chem Int Ed Engl"},{"issue":"11","key":"11536_CR99","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.2174\/1386207325666211207153943","volume":"25","author":"A Sahu","year":"2022","unstructured":"Sahu A, Mishra J, Kushwaha N (2022) Artificial intelligence (AI) in drugs and pharmaceuticals. Comb Chem High Throughput Screen 25(11):1818\u20131837. https:\/\/doi.org\/10.2174\/1386207325666211207153943","journal-title":"Comb Chem High Throughput Screen"},{"issue":"31","key":"11536_CR100","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.2174\/1568026619666190119150741","volume":"18","author":"KB Dar","year":"2018","unstructured":"Dar KB, Bhat AH, Amin S et al (2018) Modern computational strategies for designing drugs to curb human diseases: A prospect. Curr Top Med Chem 18(31):2702\u20132719. https:\/\/doi.org\/10.2174\/1568026619666190119150741","journal-title":"Curr Top Med Chem"},{"issue":"8","key":"11536_CR101","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1038\/s41591-025-03743-2","volume":"31","author":"Z Xu","year":"2025","unstructured":"Xu Z, Ren F, Wang P et al (2025) A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial. Nat Med 31(8):2602\u20132610. https:\/\/doi.org\/10.1038\/s41591-025-03743-2","journal-title":"Nat Med"},{"issue":"20","key":"11536_CR102","doi-asserted-by":"publisher","first-page":"14237","DOI":"10.1021\/acs.jmedchem.2c01454","volume":"65","author":"X Yu","year":"2022","unstructured":"Yu X, Xu J, Cahuzac KM et al (2022) Novel allosteric inhibitor-derived AKT proteolysis targeting chimeras (PROTACs) enable potent and selective AKT degradation in KRAS\/BRAF mutant cells. J Med Chem 65(20):14237\u201314260. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01454","journal-title":"J Med Chem"},{"key":"11536_CR103","doi-asserted-by":"publisher","first-page":"117948","DOI":"10.1016\/j.ejmech.2025.117948","volume":"297","author":"B Yuan","year":"2025","unstructured":"Yuan B, Ma M, Wu Y et al (2025) Discovery of novel covalent PI3K\u03b4 inhibitors bearing alaninamide moiety by lysine-targeted covalent strategy. Eur J Med Chem 297:117948. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117948","journal-title":"Eur J Med Chem"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11536-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11536-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11536-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:02:51Z","timestamp":1791266571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-026-11536-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":103,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["11536"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11536-z","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declare no conflict of interest in this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}